Skip to main content

Site notifications

Novartis Pharmaceutical Australia Pty Ltd

Regulatory activities for this sponsor.

Sponsor content

2 result(s) found, displaying 1 to 2
  • Fabhalta (iptacopan) has been approved for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (a condition where red blood cells are destroyed by the immune system).
  • AusPAR: Secukinumab

Help us improve the Therapeutic Goods Administration site